VKTX insider ownership: who sold, why, and what they still hold

What stands out

Charles Rowland Jr. sold $2.1M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Oct 27, 2025

Neil Aubuchon bought 4.5K shares for $150K, first on Mar 10, 2026.Purchase, Mar 10, 2026

A share of stake is shown for 0 of the 5 officers and directors who sold. 11 are left out

Left out: Brian Lian, Marianna Mancini, Greg Zante, Matthew Foehr, Lawson Macartney, Charles Rowland Jr., Matthew Singleton, Sarah Rouan, Neil Aubuchon, Hubert Chen and Dorothy Kelly-Gemmell (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Brian Lian

President & CEO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$14.0MTo cover taxes

Greg Zante

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.8MTo cover taxes

Marianna Mancini

Chief Operating Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.7MTo cover taxes

Charles Rowland Jr.

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.1MNo plan disclosed

Matthew Foehr

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$562KNo plan disclosed

Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

To cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Jul 29, 20263 executives sold 188K shares ($6.3M) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Brian Lian President & CEO, Director	148,517	$33.32	n/a	n/a	Jul 29, 2026	Jul 29, 2026
Greg Zante Chief Financial Officer	21,217	$33.47	n/a	n/a	Jul 29, 2026	Jul 29, 2026
Marianna Mancini Chief Operating Officer	18,217	$33.47	n/a	n/a	Jul 29, 2026	Jul 29, 2026

Common questions

Is the Viking Therapeutics, Inc. CEO selling stock?

Yes. Brian Lian sold 421K shares ($14.0M) in the past 12 months, none of it under a trading plan disclosed in the filings.

Why are Viking Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 0% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 88% were to cover taxes and 12% had no disclosed plan. A trading plan schedules sales in advance.

Are any Viking Therapeutics, Inc. insiders buying?

Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold5 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Brian Lian President & CEO, Director	$14.0M 421K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Greg Zante Chief Financial Officer	$2.8M 85K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Marianna Mancini Chief Operating Officer	$2.7M 82K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Charles Rowland Jr. Director	$2.1M 60K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Matthew Foehr Director	$562K 16K shares	Not confirmed share of stake is being verified. Why	No plan disclosed

The full ownership picture0 of 11 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Brian Lian

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Brian Lian are complete.

President & CEO, Director

n/a

−421K

n/a

Vesting, gifts, unvested awards and holding lines for Brian Lian

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brian Lian are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
65,000	$7.77	Jan 3, 2030	$1.7M
360,000	$17.40	Jan 3, 2034	$5.7M
78,300	$42.89	Jan 3, 2035	$0
176,300	$35.42	Jan 2, 2036	$0

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Marianna Mancini

Chief Operating Officer

n/a

−82K

n/a

Vesting, gifts, unvested awards and holding lines for Marianna Mancini

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Marianna Mancini are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1	$4.68	Mar 31, 2030	$29
18,574	$7.77	Jan 3, 2030	$474K
87,000	$4.88	Jan 3, 2032	$2.5M
153,000	$8.52	Jan 3, 2033	$3.8M
155,000	$17.40	Jan 3, 2034	$2.5M
37,200	$42.89	Jan 3, 2035	$0
91,000	$35.42	Jan 2, 2036	$0

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Greg Zante

Chief Financial Officer

n/a

−85K

n/a

Vesting, gifts, unvested awards and holding lines for Greg Zante

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Greg Zante are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
153,000	$8.52	Jan 3, 2033	$3.8M
155,000	$17.40	Jan 3, 2034	$2.5M
60,000	$4.88	Jan 3, 2032	$1.7M
37,200	$42.89	Jan 3, 2035	$0
91,000	$35.42	Jan 2, 2036	$0

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Matthew Foehr

Director

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Matthew Foehr

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Matthew Foehr are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,000	$18.28	Jan 2, 2034	$481K
18,800	$41.12	Jan 2, 2035	$0
20,400	$35.42	Jan 2, 2036	$0

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Lawson Macartney

Director

n/a

Vesting, gifts, unvested awards and holding lines for Lawson Macartney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lawson Macartney are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,000	$5.80	Jan 4, 2031	$550K
32,000	$18.28	Jan 2, 2034	$481K
18,800	$41.12	Jan 2, 2035	$0
20,400	$35.42	Jan 2, 2036	$0

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Charles Rowland Jr.

Director

n/a

−60K

n/a

Vesting, gifts, unvested awards and holding lines for Charles Rowland Jr.

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Charles Rowland Jr. are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,000	$18.28	Jan 2, 2034	$481K
18,800	$41.12	Jan 2, 2035	$0
20,400	$35.42	Jan 2, 2036	$0

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Matthew Singleton

Director

n/a

Vesting, gifts, unvested awards and holding lines for Matthew Singleton

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Matthew Singleton are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,000	$18.28	Jan 2, 2034	$481K
18,800	$41.12	Jan 2, 2035	$0
20,400	$35.42	Jan 2, 2036	$0

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Sarah Rouan

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sarah Rouan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sarah Rouan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,000	$4.88	Jan 3, 2032	$313K
32,000	$18.28	Jan 2, 2034	$481K
18,800	$41.12	Jan 2, 2035	$0
20,400	$35.42	Jan 2, 2036	$0

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Neil Aubuchon

Chief Commercial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Neil Aubuchon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Neil Aubuchon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
180,000	$31.76	Jan 12, 2036	$280K

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Hubert Chen

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Hubert Chen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hubert Chen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
190,000	$31.27	Jun 1, 2036	$389K

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Dorothy Kelly-Gemmell

Director

n/a

Vesting, gifts, unvested awards and holding lines for Dorothy Kelly-Gemmell

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dorothy Kelly-Gemmell are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
40,800	$31.74	Aug 1, 2036	$64K

Estimate: options held × ($33.32 − strike price), using the most recent insider trade price on Form 4 (Jul 29, 2026), not a market close.

Holdings and share of stake for Viking Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$22.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $22.3M across 664,041 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

No plan disclosed · $22.3M

No plan disclosed · $2.7M

Sales with no 10b5-1 plan and no tax reference in the filing. $2.1M of it is Charles Rowland Jr.. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Charles Rowland Jr., Oct 27, 2025

Taxes

$19.6M of sales (87.9%) cite tax obligations in their footnotes. Example: Greg Zante, Jul 29, 2026

Purchases · 1 buyer (1 trade)

1 officer or director bought shares in this period, in 1 trade(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 10 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Brian Lian President & CEO, Director	421K	$14.0M	0%	63%	Oct 28, 2025 to Jul 29, 2026
Greg Zante Chief Financial Officer	85K	$2.8M	0%	13%	Oct 28, 2025 to Jul 29, 2026
Marianna Mancini Chief Operating Officer	82K	$2.7M	0%	12%	Oct 28, 2025 to Jul 29, 2026
Charles Rowland Jr. Director	60K	$2.1M	0%	10%	Oct 27, 2025 to Oct 27, 2025
Matthew Foehr Director	16K	$562K	0%	3%	Jan 2, 2026 to Jan 2, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$3.9M	$0	$1.8M	$2.1M
Nov 2025	$0	$0	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$12.1M	$0	$11.5M	$562K
Feb 2026	$0	$0	$0	$0
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$6.3M	$0	$6.3M	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

In line with the past 5 years. 5 insiders sold; the average is 3 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	664K	5	$22.3M
Oct 16, 2025 1 year earlier	495K	6	$26.2M
Oct 16, 2024 2 years earlier	1.39M	5	$75.0M
Oct 17, 2023 3 years earlier	1.17M	5	$21.3M
Oct 17, 2022 4 years earlier	0	0	$0
Oct 17, 2021 5 years earlier	0	0	$0

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty11 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Viking Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology216 filings on record, 22 filed in the 12-month period, and how we read them

All 216 Forms 3, 4 and 5 on record for Viking Therapeutics, Inc. (SEC CIK 1607678), filed from Apr 28, 2015 to Aug 7, 2026; 22 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (6)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Michael Morneau	Jan 19, 2021	213,935 shares, last reported balance as of Jan 19, 2021
LIGAND PHARMACEUTICALS INC	Aug 28, 2020	5,819,383 shares, last reported balance as of Aug 26, 2020
Stephen Webster	Jan 3, 2020	8,000 shares, last reported balance as of May 29, 2018
Hiroko Masamune	Jan 3, 2019	116,063 shares, last reported balance as of Jan 3, 2019
Rochelle Hanley	May 5, 2016	160,836 shares, last reported balance as of May 4, 2016
Michael Dinerman	May 6, 2015	694,116 shares, last reported balance as of May 4, 2015

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Viking Therapeutics, Inc. insiders sold $22.3M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Viking Therapeutics, Inc. CEO selling stock?

Why are Viking Therapeutics, Inc. insiders selling?

Are any Viking Therapeutics, Inc. insiders buying?

The evidence

No plan disclosed · $2.7M

Taxes

Purchases · 1 buyer (1 trade)

Sales by month